Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

Novartis' Cosentyx® sets new benchmark in psoriasis with robust 5-year sustained Phase III efficacy

worldpharmanewsSeptember 18, 2017

Tag: Novartis , psoriasis

PharmaSources Customer Service